Moberg Pharma (MOB) Panoramica del titolo
Moberg Pharma AB (publ), azienda farmaceutica, sviluppa e commercializza prodotti medici principalmente in Svezia. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
MOB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 75.3% sottovalutato sconto intrinseco
5022.2%Revenue growth p.a.
3.7k
23
2
55
Concorrenti di Moberg Pharma AB (publ)
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | SEK 11.50 |
| Massimo di 52 settimane | SEK 14.12 |
| Minimo di 52 settimane | SEK 7.25 |
| Beta | 1.05 |
| Variazione di 1 mese | 9.52% |
| Variazione a 3 mesi | 21.95% |
| Variazione di 1 anno | 46.78% |
| Variazione a 3 anni | -53.82% |
| Variazione a 5 anni | -79.13% |
| Variazione dall'IPO | -95.99% |
Notizie e aggiornamenti recenti
MOB: Dual Terbinafine Suppliers And Broader Mandate Will Support Future Re Rating Potential
Analysts now hold the fair value estimate for Moberg Pharma steady at SEK 13.0, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that the recent review has not altered their SEK-based price target framework. What's in the News Moberg Pharma plans to propose an amendment to its articles of association at the AGM scheduled for 21 May 2026.MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential
Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).MOB: Dual Supplier Approval Will Support Future Re Rating Potential
Analysts have maintained their SEK fair value estimate for Moberg Pharma at SEK 13.0, with unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. This suggests their view on the company’s risk and earnings outlook remains essentially intact.Recent updates
MOB: Dual Terbinafine Suppliers And Broader Mandate Will Support Future Re Rating Potential
Analysts now hold the fair value estimate for Moberg Pharma steady at SEK 13.0, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that the recent review has not altered their SEK-based price target framework. What's in the News Moberg Pharma plans to propose an amendment to its articles of association at the AGM scheduled for 21 May 2026.MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential
Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).MOB: Dual Supplier Approval Will Support Future Re Rating Potential
Analysts have maintained their SEK fair value estimate for Moberg Pharma at SEK 13.0, with unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. This suggests their view on the company’s risk and earnings outlook remains essentially intact.MOB: Stable Assumptions And Profitability Outlook Will Support Future Re Rating
Analysts have maintained their SEK 13.0 price target for Moberg Pharma, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: SEK 13.0 is unchanged, with only rounding differences between the previous SEK 13 and the current SEK 13.0 figure.MOB: Higher Profitability Assumptions Will Support Re Rating Of Undervalued Shares
Analysts have adjusted their price target on Moberg Pharma to SEK 13.0. This reflects updated views on revenue growth, profit margin and a lower future P/E assumption. Valuation Changes Fair Value: SEK 13.0 is unchanged, indicating no revision to the overall price estimate.MOB: Undervalued Shares Will Rely On Stable Assumptions To Re-Rate
Analysts have kept their price target for Moberg Pharma steady at SEK 13.00. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.MOB: Europe Licensing Agreement Will Support Future Share Price Upside
Analysts have kept their price target for Moberg Pharma steady at SEK 13.0. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E despite the latest review of their model inputs. What's in the News Karo Healthcare AB and Moberg Pharma AB have signed an exclusive licensing agreement for the commercialisation of MOB-015 in 19 European markets, covering a population of about 500 million people (Key Developments).MOB: Europe Licensing Agreement Will Support Strong Future Share Price Upside
Analysts have maintained their price target on Moberg Pharma at SEK 13.0, with unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This indicates their core view on the stock remains intact for now.MOB: Exclusive European Licensing Deal Will Drive Strong Future Share Upside
Analysts have marginally adjusted their price target on Moberg Pharma, reiterating a fair value of SEK 13.0 per share as they maintain their assumptions for discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News Karo Healthcare AB signs an exclusive licensing agreement with Moberg Pharma for the commercialisation of MOB-015 across 19 European markets, including all major EU countries and the United Kingdom, ensuring a coordinated launch under the Lamisil brand (Company announcement) The licensing deal grants Karo responsibility for marketing, distribution, and sales in 11 countries where MOB-015 is already approved but not yet launched, accelerating the product’s European rollout (Company announcement) MOB-015, a new topical terbinafine formulation, demonstrates mycological cure rates of 76 percent in registration studies, delivering efficacy on par with oral treatment and addressing historical challenges in penetrating the nail (Company announcement) The agreement provides Moberg Pharma with access to a total addressable population of about 500 million people in Europe, significantly expanding the commercial potential of MOB-015 (Company announcement) Valuation Changes Fair Value: Unchanged at SEK 13.0 per share, reflecting a stable outlook for Moberg Pharma’s intrinsic valuation.MOB: Exclusive Licensing Deal Will Unlock Major European Market Launches
Analysts have maintained their price target for Moberg Pharma at SEK 13.00. This reflects continued confidence in the company's earnings outlook and growth potential.MOB: Licensing Agreement Will Drive Expansion Across Europe This Year
Analysts have raised their price target for Moberg Pharma from SEK 11 to SEK 13. This change reflects updated forecasts that consider notable shifts in anticipated revenue growth, profitability, and market conditions.We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn
Nov 07
Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being
May 16
Norway Expansion And EU Approvals Will Strengthen Future Position
Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth
Feb 12We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Sep 14Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 08Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Nov 16Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
Jan 17Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares
Dec 03
Rendimenti per gli azionisti
| MOB | SE Pharmaceuticals | SE Mercato | |
|---|---|---|---|
| 7D | -7.1% | -1.6% | -1.9% |
| 1Y | 46.8% | -18.6% | 11.0% |
Ritorno vs Industria: MOB ha superato il Swedish Pharmaceuticals che ha restituito -18.6 % nell'ultimo anno.
Rendimento vs Mercato: MOB ha superato il mercato Swedish che ha restituito 11 % nell'ultimo anno.
Volatilità dei prezzi
| MOB volatility | |
|---|---|
| MOB Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 8.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.8% |
Prezzo delle azioni stabile: MOB non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swedish.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di MOB è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2006 | 6 | Anna Ljung | www.mobergpharma.se |
Moberg Pharma AB (publ), azienda farmaceutica, sviluppa e commercializza prodotti medici principalmente in Svezia. Offre MOB-015 per il trattamento dei funghi delle unghie con il marchio Terclara. L'azienda era precedentemente nota come Moberg Derma AB (publ) e ha cambiato nome in Moberg Pharma AB (publ) nel maggio 2013.
Moberg Pharma AB (publ) Riepilogo dei fondamenti
| MOB statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | SEK 540.51m |
| Utili (TTM) | -SEK 27.24m |
| Ricavi(TTM) | SEK 13.54m |
39.9x
Rapporto P/S-19.8x
Rapporto P/EMOB è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MOB Conto economico (TTM) | |
|---|---|
| Ricavi | SEK 13.54m |
| Costo del fatturato | SEK 5.86m |
| Profitto lordo | SEK 7.68m |
| Altre spese | SEK 34.92m |
| Utili | -SEK 27.24m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
May 12, 2026
| Utile per azione (EPS) | -0.58 |
| Margine lordo | 56.73% |
| Margine di profitto netto | -201.18% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato MOB nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/03 17:20 |
| Prezzo dell'azione a fine giornata | 2026/04/30 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Moberg Pharma AB (publ) è coperta da 4 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Klas Pyk | Nordea Markets |
| Mats Hyttinge | Redeye |